Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohort In patients who previously received asciminib, cumulative MMR rate was 52%, with 38% of patients achieving MMR by 24...
Hence then, the article about enliven therapeutics announces oral presentation at the eha 2026 congress featuring additional positive phase 1 clinical trial data for elvn 001 in cml was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML )
Also on site :
- Welcome to the mega-war: Mideast and European conflicts merge, sucking in more countries along the way—even ones claiming neutrality
- Total eclipse, shooting stars, and the Milky Way: Why Aug. 12 could be the greatest single day and night for skywatching for years
- Charges dropped against ex-Olympian over Reflecting Pool damage after Trump admin admits ‘flawed installation’